Can INNOVENT BIOLOGICS INC COMMON SHARES CAY (OTCMKTS:IVBXF)’s Tomorrow Be Different? The Stock Had Decline in Shorts

The stock of INNOVENT BIOLOGICS INC COMMON SHARES CAY (OTCMKTS:IVBXF) registered a decrease of 45.55% in short interest. IVBXF’s total short interest was 293,500 shares in September as published by FINRA. Its down 45.55% from 539,000 shares, reported previously.

The stock increased 0.66% or $0.02 during the last trading session, reaching $3.07. About 21,151 shares traded or Infinity% up from the average. Innovent Biologics, Inc. (OTCMKTS:IVBXF) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Innovent Biologics, Inc. operates as a development-stage biopharmaceutical firm in China. The company has market cap of $. The firm develops a platform for the discovery, development, manufacture, and commercialization of antibody drug candidates in the fields of oncology, ophthalmology, and autoimmune and metabolic diseases. It currently has negative earnings. The Company’s principal drug candidates, including Tyvyt , anti-PD-1 monoclonal antibody for the treatment of gastric cancer, solid tumors, and esophageal carcinoma; IBI-301, a rituximab biosimilar for the treatment of chronic lymphocytic leukemia and rheumatoid arthritis; IBI-303, an adalimumab biosimilar for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriasis; and IBI-305, a bevacizumab biosimilar for the treatment of oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.